Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03257163 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | active not recruiting | Phase 2 | 40 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02473536 | Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | active not recruiting | Phase 1 / Phase 2 | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 16, 2026 |
| clinicaltrials |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | active not recruiting | Phase 2 | 110 | Ana C Garrido-Castro, MDOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04539808 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 2 | 42 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04028167 | Induction FLOT With CROSS CRT for Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03673124 | Ribociclib and Letrozole Treatment in Ovarian Cancer | active not recruiting | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT02827877 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | active not recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05949021 | OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Mridula George, MDOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06519097 | Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) | active not recruiting | Phase 2 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 13, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04821284 | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 120 | Flemming ForsbergOTHER | 2 | Nov 4, 2025 | clinicaltrials |
| NCT05779943 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | active not recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04106414 | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment | active not recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04009044 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | active not recruiting | Phase 2 | 156 | Northwestern UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT04888312 | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients(OPTIMIZE-1) | active not recruiting | Phase 1 / Phase 2 | 94 | Alligator Bioscience ABINDUSTRY | 3 | Oct 8, 2025 | clinicaltrials |
| NCT03245541 | Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT02393794 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 / Phase 2 | 51 | Priyanka SharmaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03438708 | Prior Axitinib as a Determinant of Outcome of Renal Surgery(PADRES) | active not recruiting | Phase 2 | 22 | University of California, San DiegoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer(NESCIO) | active not recruiting | Phase 2 | 69 | The Netherlands Cancer InstituteOTHER | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03515798 | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer(PELICAN) | active not recruiting | Phase 2 | 52 | Institut Paoli-CalmettesOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT00788671 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | active not recruiting | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1) | active not recruiting | Phase 2 | 130 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2026source: clinicaltrials